SAN DIEGO--(BUSINESS WIRE)--Neuropore Therapies, Inc., a biopharmaceutical company discovering and developing novel therapeutics for the treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative disorders announced today that it received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.
“We are very pleased to receive this grant from The Michael J. Fox Foundation. We are confident that with this assistance from MJFF our TLR2 program will quickly advance to testing our lead compounds in our well-established platform of in vitro and in vivo models of Parkinson’s disease,” stated Douglas Bonhaus, Chief Scientific Officer of Neuropore.
Including the TLR2 antagonist program, Neuropore Therapies is developing an exciting pipeline aimed at pathological protein clearance through autophagy as well as attenuation of the pathological immune responses. Both the accumulation of pathological proteins and neuroinflammation are dysfunctions underlying neurodegenerative disease.
About Neuropore Therapies, Inc. (NPT®)
Neuropore Therapies is developing novel small molecule therapeutics to treat and slow the progression of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. The approach being taken by Neuropore is to target an underlying pathological process common to these disorders – the accumulation of toxic oligomeric aggregates of misfolded neuronal proteins in cell membranes. By preventing the formation and enhancing the clearance of these toxic aggregates synaptic function may be restored and neurodegenerative processes slowed.